See Table 1 and 4 legends for expansion of other abbreviations and GRADE Working Group grades of evidence. a CI includes values suggesting both bene t and harm. b Low number of events. c Reported deaths from Enden et al90 (CAVENT). d Estimate taken from Watson et al.229 The 1 study included for this outcome was Enden et al90 (CAVENT). e Baseline risks for nonfatal recurrent VTE and for major bleeding derived from Douketis et al.231 f Most of bleeding events occur during the rst 7 d. g This estimate is based on the Watson et al.229 The 1 study included for this outcome was Enden et al90 (CAVENT). For PTS at 6 mo, published data from Enden et al90 (CAVENT) provide an estimate RR of 0.93 (0.61-1.42) via Watson et al.229 h This estimate is based on the ndings of the VETO study.232 i For severe PTS, assuming the same RR of 0.46 and a baseline risk of 13.8%,232 the absolute reduction is 75 fewer severe PTS per 1,000 (from 29 fewer to 138 fewer) over 2 y. j Reported patency from Enden et al90 (CAVENT). k Open-label. l Disease-speci c QoL (VEINES-QOL) estimate used at 24 mo according to treatment allocation. m Generic QoL (EQ-5D) at 24 mo according to treatment allocation estimate is mean difference 0.04 (-0.01 to 0.17). Bibliography: Watson et al229 used for all outcomes except patency and QoL; Enden et al90 used for patency estimates; Enden et al230 used for QoL estimates. uncertain, we consider that anticoagulant therapy alone is an acceptable alternative to CDT in all patients with acute DVT who do not have impending venous gangrene. 16. In patients with acute proximal DVT of the leg, we suggest anticoagulant therapy alone over CDT (Grade 2C). 